Plain-English translation of NCT05521412 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called [161Tb]Tb-PSMA-I&T for men with advanced prostate cancer that has progressed despite hormone therapy and chemotherapy. The medication is radioactive and designed to target cancer cells that have a specific marker on their surface. Researchers want to find the right dose and understand how safe and effective this treatment is.
Men with advanced prostate cancer often run out of treatment options when their cancer stops responding to standard medications and chemotherapy. This trial exists to see whether this new radioactive treatment could help patients whose cancer has become resistant to current therapies.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication once every 6 weeks, with up to 6 doses given over approximately 6 months. The study includes a dose-escalation phase where the first patients receive lower doses to establish safety, followed by a dose-expansion phase. You would need to complete regular blood tests, imaging scans, and clinic visits to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Australia